A real-world study presented at finds zuranolone's PPD symptom improvements were sustained through day 90.
|Articles|September 4, 2014
Antiprogestin CDB-2914 promising for uterine fibroids (VIDEO)
William Fredette, MD, discusses the benefits of Antiprogestin CDB-2914 for reducing uterine fibroid size and bleeding, and improving quality of life for affected women, as reported in the journal Fertility and Sterility. Video provided by The Doctor's Channel.
Advertisement
William Fredette, MD, discusses the benefits of Antiprogestin CDB-2914 for reducing uterine fibroid size and bleeding, and improving quality of life for affected women, as reported in the journal
This video is part of the
Video provided by:
Advertisement
Related to this article
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Hugh Taylor, MD, explains that imaging in endometriosis is best for ruling out other causes of pelvic pain and cannot exclude the diagnosis.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Survey: 51% of US-women report negative healthcare experiences
2
FDA holding public meeting on testosterone use in menopausal women
3
Contemporary OB/GYN Weekly Review: Testosterone evidence, ECV counseling, and more
4
Earlier menopause associated with less favorable functional, structural neurological outcomes
5